Model-Based Meta-Analysis (MBMA) isn’t just another tool—it’s a strategic powerhouse for unlocking data-driven insights across clinical development.
If you missed our live session, you can now watch it on demand to learn how MBMA is helping global pharma teams bridge data gaps, support regulatory submissions, and make confident go/no-go decisions.
In this webinar, Certara and GSK experts demonstrate the real-world value of MBMA through case studies in hepatitis B, inflammatory diseases, and oncology.
You’ll hear from:
- Matt Zierhut, Vice President, MBMA Capability Lead, Certara Drug Development Solutions
- Nathan Hanan, Director, Clinical Pharmacology Modeling & Simulation at GSK
- Richard Franzese, Director of Clinical Pharmacology Modeling and Simulation at GSK
- Monica Simeoni, Fellow and Director, Clinical Pharmacology Modelling & Simulation at GSK
Watch Now to Learn How MBMA Can Help You:
- Make faster, evidence-based decisions
- Predict clinical outcomes using aggregated trial data
- Optimize dose selection and trial design
- Strengthen regulatory submissions with a MIDD-aligned approach
Access the Webinar On Demand
